Conditional Reimbursement in Chronic Pain Rehabilitation: Navigating Evidence Gaps and Patient Ac...
Healthcare stakeholders were informed in the Netherlands that Chronic Pain Rehabilitation through Interdisciplinary Medical Specialist Rehabilitation (IMSR) will be removed from the Dutch basic health insurance package for most patients. Under the new ruling by Zorginstituut Nederland, chronic pa...
Advancing Psychedelic Therapy Access for Treatment-Resistant Mental Illness
An Executive Order signed by President Donald J. Trump on April 18, 2026, will significantly advance psychedelic therapy access for serious mental illness. By removing regulatory and scheduling barriers, the order directs the FDA to issue Commissioner’s National Priority Vouchers for eligible psy...
Effective Hypertension Control Interventions in Underserved Populations
Hypertension control interventions delivered through a scalable, team-based care model significantly reduce blood pressure among low-income adults, according to a National Institutes of Health-supported clinical trial. Conducted in federally qualified health centers, the program combined intensiv...
Null Link Confirmed: Prenatal Acetaminophen Autism Risk Study in Denmark
A major nationwide Danish cohort study has found no link between maternal acetaminophen use during pregnancy and autism in children. The new evidence on prenatal acetaminophen autism risk should reassure clinicians and expectant mothers, as both population-wide and sibling-controlled analyses sho...
Amyloid-Beta Treatment Impact: Limited Clinical Benefits and Increased Risks in Early Alzheimer’s...
Amyloid-Beta Treatment Impact on people with early Alzheimer’s disease is minimal, according to a major new Cochrane review. The analysis of 17 randomized controlled trials involving more than 20,000 participants found that amyloid-beta-targeting monoclonal antibodies deliver only trivial improve...
HIV Prevention Partnerships: Expanding Access to Lenacapavir for Global Impact
HIV Prevention Partnerships between PEPFAR, The Global Fund, and Gilead Sciences are accelerating access to twice-yearly injectable lenacapavir for HIV pre-exposure prophylaxis (PrEP) in high-burden countries.
Unprecedented Speed to Sub-Saharan Africa
This additional i...







